Loading...
Projects / Programmes
Modifikacije farmacevtsko pomembnih proteinov za lažjo izolacijo in izboljšanje lastnosti (Slovene)
Research activity
| Code | Science | Field | Subfield |
|---|---|---|---|
| 1.05.00 | Natural sciences and mathematics | Biochemistry and molecular biology |
| Code | Science | Field |
|---|---|---|
| P004 | Natural sciences and mathematics | Biochemistry, Metabolism |
| P310 | Natural sciences and mathematics | Proteins, enzymology |
Keywords
protein, protein engineering, isolation, stabilization, immobilization, renaturation, pharmaceutical use, TNF, analogs, receptor p55, chaperons
Evaluation
(metodology)
Citations
Citations for bibliographic records in COBIB.SI that are linked to records in citation databases
Organisations (2) , Researchers (9)
0104 National Institute of Chemistry
| no. | Code | Name and surname | Research area | Role | Period | No. of publicationsNo. of publications |
|---|---|---|---|---|---|---|
| 1. | 06108 | Biotechnology | Head | 1999 - 2001 | 226 | |
| 2. | 17275 | Researcher | 1999 - 2001 | 0 | ||
| 3. | 06135 | Biochemistry and molecular biology | Researcher | 1999 - 2001 | 1,071 | |
| 4. | 00385 | Biotechnology | Researcher | 2000 - 2001 | 227 | |
| 5. | 17276 | Researcher | 1999 - 2001 | 2 |
0258 Lek Pharmaceutical Company d.d.
| no. | Code | Name and surname | Research area | Role | Period | No. of publicationsNo. of publications |
|---|---|---|---|---|---|---|
| 1. | 11108 | Biotechnology | Researcher | 1999 - 2001 | 34 | |
| 2. | 16171 | Biotechnology | Researcher | 1999 - 2001 | 51 | |
| 3. | 01494 | Biotechnology | Researcher | 1999 - 2001 | 167 | |
| 4. | 00830 | Biotechnology | Researcher | 1999 - 2001 | 164 |
Abstract
For introductory clinical trials of anti-tumor therapy with our newly developed TNF analogs, a substance of superior quality is needed. Therefore, a thorough study and application of rational approaches of production, including genetic and protein engineering, is necessary. Our project involves study of protein modifications leading to simplified and more economic isolation procedures, simple immobilization on solid supports and new approaches of renaturation. Besides TNF analogs, soluble TNF receptor p55 and chaperon GroEL from E. coli will be used as model molecules.